Search

Your search keyword '"Yurdaydin C"' showing total 565 results

Search Constraints

Start Over You searched for: Author "Yurdaydin C" Remove constraint Author: "Yurdaydin C"
565 results on '"Yurdaydin C"'

Search Results

101. Serum cytotoxin and oxidant stress markers in N-acetylcysteine treated thioacetamide hepatotoxicity of rats

102. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis

107. Tumour necrosis factor-alpha, interleukin-10, interferon-gamma and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta

109. 435 ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA

111. T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study

112. Entecavir Treatment of Chronic Hepatitis D

116. 525 TENOFOVIR MONOTHERAPY FOR NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS FOLLOWED FOR 30 MONTHS

117. OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE

118. T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice

122. 731 EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B

123. P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B

124. 382 PROLONGED INTRAHEPATIC HEPATITIS DELTA ANTIGEN PERSISTENCE AFTER LIVER TRANSPLANTATION (LTX) DESPITE RAPID EARLY SERUM HDVRNA DECLINE AFTER LTX

125. F-36 Effectiveness and safety of tenofovir disoproxil fumarate in field practice: A multicenter European cohort study of 737 patients with chronic hepatitis B

126. Anti-HDV-IgM testing in hepatitis delta revisited: Correlations with disease activity and response to pegylated interferon alfa-2a treatment

127. 321 ANTI-HDV-IGM TESTING IN HEPATITIS DELTA REVISITED: CORRELATIONS WITH DISEASE ACTIVITY AND RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT

132. 683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY

139. [4] 72 WEEK DATA OF THE HIDIT-1 TRIAL: A MULTICENTER RANDOMISED STUDY COMPARING PEGINTERFERON α-2a PLUS ADEFOVIR VS. PEGINTERFERON α-2a PLUS PLACEBO VS. ADEFOVIR IN CHRONIC DELTA HEPATITIS

141. [487] PREDICTORS OF HBsAg REDUCTION IN HBsAg- NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) ALONE OR IN COMBINATION WITH LAMIVUDINE

143. Pegylated interferon-alfa–2a plus adefovir combination therapy is superior to pegylated interferon-alfa–2a alone or adefovir monotherapy in reducing HBsAg levels in HDV-coinfected patients with low HBV viremia

144. Significance of HBsAg and HDVRNA levels in patients with delta hepatitis recruited in the Hep-Net/International HDV intervention trial

146. P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®]

149. Cytotoxic CD4-positive T cells in viral hepatitis

Catalog

Books, media, physical & digital resources